Illumina CFO Predicts GWAS Market Will Return to 'Normal State' in 2010
September 22, 2009
Illumina CFO Predicts GWAS Market Will Return to 'Normal State' in 2010
Despite experiencing "some weakness" in demand for its whole-genome genotyping chips in recent quarters, Illumina expects the genome-wide association studies market to revive by the middle of next year, and believes its array business will continue to grow, driven by the agricultural biotechnology market and custom projects.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- What's the Future of Array-Based GWAS? Sequencing Tech, Study Design, Funding To Impact Growth
September 15, 2009 / BioArray News - Q&A: Chinese GWAS Expert Yongyong Shi Makes the Case for Population-Specific Arrays
December 18, 2012 / BioArray News - Illumina CEO Discusses ENCODE, GWAS, and NIH Funding at Investor Conference
September 18, 2012 / BioArray News - Next Round of GWAS a 'Wait-and-See Situation,' Says Illumina CEO
June 14, 2011 / BioArray News - Illumina CEO 'Optimistic' about Array Business as Q1 Sales Spike 47 Percent
May 3, 2011 / BioArray News